Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
14 June 2019Americas

GSK unites with CRISPR pioneer Doudna

British-based pharmaceutical company GSK has entered into a five-year collaboration with the U niversity of California to explore how gene mutations cause disease and accelerate drug discovery.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids